<div id="readability-page-1"><h3>Claim 30% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Duality Biotherapeutics, Inc. ( (HK:9606) ) has shared an announcement. Duality Biotherapeutics has announced a series of senior management and board changes effective March 23, 2026, including the resignation of executive director Si Wen from the board and the remuneration committee for personal career reasons, while she continues to lead human resources. The company has simultaneously appointed long-time R&amp;D leader Hua Haiqing as an executive director, named Zhang Shaoren as chief financial officer, and added Zhu Zhongyuan to the remuneration committee, signaling a reconfiguration of governance and financial leadership to support its drug development strategy. Hua, who has nearly 15 years of drug discovery experience at international and Chinese pharmaceutical organizations and has led the group’s pipeline and R&amp;D strategy since 2021, will serve a three-year term as executive director under an appointment letter and receive compensation linked to his broader role in the group. The reshuffle aligns experienced scientific and financial executives more closely with the board and key committees, potentially strengthening oversight of R&amp;D investment, capital allocation and incentive structures as Duality Biotherapeutics advances its pipeline in a competitive biotech landscape. The most recent analyst rating on (HK:9606) stock is a Buy with a HK$493.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page. More about Duality Biotherapeutics, Inc. Duality Biotherapeutics, Inc. is a biopharmaceutical company focused on drug discovery and development, operating through a group structure with subsidiaries. The company develops new drugs and therapeutic pipelines, targeting innovative R&amp;D-driven growth in the global healthcare and life sciences markets. Average Trading Volume: 736,438 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$25.26B </div>

159837

Duality Biotherapeutics, Inc. has announced significant changes to its board and finance leadership effective March 23, 2026. Executive director Si Wen will resign, while Hua Haiqing is appointed as executive director and Zhang Shaoren as CFO. This restructuring aims to enhance governance and financial oversight to support the company's drug development strategy. The recent analyst rating for Duality Biotherapeutics (HK:9606) is a Buy with a price target of HK$493.00, reflecting confidence in the company's growth potential in the biotech sector.

Tip Ranks

Invesco Biotechnology & Genome ETF

iShares US Pharma

E Fund CSI Biotechnology Theme ETF

Sensei Biotherapeutics

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Sutro Biopharma

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

Ping An CSI Medicine and Medical Device Innovation ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

DUALITYBIO-B

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Atara Biotherap

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

ChinaAMC SSE Health Care ETF Initiating Fund

VG Health

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

Health Care Select Sector SPDR

Penghua SSE STAR Biology and Medicine ETF

Bioxcel Therap

First Trust NYSE Arca Biotech Index Fd

Guotai CSI Bio-medicine ETF

Unity Biotechnology

SPDR S&P Biotech

Duality Biotherapeutics Reshapes Board and Finance Leadership to Back R&D Strategy